Skip to main content
Veterinary Medicines

K1 KEYVIT 50 mg tablets for dogs

Authorised
  • Phytomenadione

Product identification

Medicine name:
K1 KEYVIT 50 mg tablets for dogs
Keyvit 50 mg comprimidos para cães
Active substance:
  • Phytomenadione
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Phytomenadione
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QB02BA01
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:
  • Box containing 2 aluminium and PVC-aluminium-oPA thermosealed blisters of 7 tablets
  • Box containing 1 aluminium and PVC-aluminium-oPA thermosealed blister of 7 tablets
  • Box containing 4 aluminium and PVC-aluminium-oPA thermosealed blisters of 7 tablets
  • Box containing 3 aluminium and PVC-aluminium-oPA thermosealed blisters of 7 tablets
  • Box containing 12 aluminium and PVC-aluminium-oPA thermosealed blisters of 7 tablets
  • Box containing 5 aluminium and PVC-aluminium-oPA thermosealed blisters of 7 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Nextmune Italy S.r.l.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 1463/01/21DFVPT
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0358/001
Concerned member states:
  • Belgium
  • France
  • Greece
  • Italy
  • Latvia
  • Lithuania
  • Poland
  • Portugal
  • Romania
  • Spain

Documents

Combined File of all Documents

English (PDF)
Published on: 23/01/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."